Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Gerber

Showing results (161-170 of 190) with videos related to

Pageof 19
Sort By:
Neuro-Oncology|June 5, 2024
Risk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa-Results of the HIT 2000 trialMartin Mynarek, Anne Rossius, Anika Guiard, et al.
Neuro-Oncology|January 30, 2023
Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroupsSvenja Tonn, Andrey Korshunov, Denise Obrecht, et al.
JAMA Oncology|October 17, 2024
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical TrialNathalie Gaspar, Giun-Yi Hung, Sandra J Strauss, et al.
JCO Precision Oncology|June 26, 2023
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORMAnna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, et al.
Neuro-Oncology|December 1, 2021
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumorsFrançois Doz, Cornelis M van Tilburg, Birgit Geoerger, et al.
European Journal of Cancer (Oxford, England : 1990)|October 31, 2020
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortiumAlba Rubio-San-Simón, Nicolas André, Maria Giuseppina Cefalo, et al.
Acta Neuropathologica|October 11, 2025
Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORMElke Pfaff, Kathrin Schramm, Mirjam Blattner-Johnson, et al.
Advances in Radiation Oncology|December 11, 2020
Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma - A Report From the HIT 2000 TrialStefan Dietzsch, Felix Placzek, Klaus Pietschmann, et al.
Acta Neuropathologica|February 2, 2025
MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade gliomaLea L Friker, Thomas Perwein, Andreas Waha, et al.
Neuro-Oncology|December 29, 2019
Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumorsMichael C Frühwald, Martin Hasselblatt, Karolina Nemes, et al.
Pageof 19

Showing results (161-170 of 190) with videos related to

Sort By:
Pageof 19
Neuro-Oncology|June 5, 2024
Risk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa-Results of the HIT 2000 trialMartin Mynarek, Anne Rossius, Anika Guiard, et al.
Neuro-Oncology|January 30, 2023
Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroupsSvenja Tonn, Andrey Korshunov, Denise Obrecht, et al.
JAMA Oncology|October 17, 2024
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical TrialNathalie Gaspar, Giun-Yi Hung, Sandra J Strauss, et al.
JCO Precision Oncology|June 26, 2023
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORMAnna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, et al.
Neuro-Oncology|December 1, 2021
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumorsFrançois Doz, Cornelis M van Tilburg, Birgit Geoerger, et al.
European Journal of Cancer (Oxford, England : 1990)|October 31, 2020
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortiumAlba Rubio-San-Simón, Nicolas André, Maria Giuseppina Cefalo, et al.
Acta Neuropathologica|October 11, 2025
Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORMElke Pfaff, Kathrin Schramm, Mirjam Blattner-Johnson, et al.
Advances in Radiation Oncology|December 11, 2020
Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma - A Report From the HIT 2000 TrialStefan Dietzsch, Felix Placzek, Klaus Pietschmann, et al.
Acta Neuropathologica|February 2, 2025
MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade gliomaLea L Friker, Thomas Perwein, Andreas Waha, et al.
Neuro-Oncology|December 29, 2019
Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumorsMichael C Frühwald, Martin Hasselblatt, Karolina Nemes, et al.
Pageof 19